RDHL - RedHill Biopharma Ltd.
IEX Last Trade
6.91
0.360 5.210%
Share volume: 0
Last Updated: Fri 27 Dec 2024 08:07:43 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$6.55
0.36
5.50%
Fundamental analysis
15%
Profitability
15%
Dept financing
13%
Liquidity
75%
Performance
0%
Performance
5 Days
3.64%
1 Month
-17.71%
3 Months
-24.10%
6 Months
1,623.68%
1 Year
374.64%
2 Year
18.83%
Key data
Stock price
$6.91
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.36 - $12.50
52 WEEK CHANGE
$348.63
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Dror Ben-Asher
Region: US
Website: redhillbio.com
Employees: 210
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: redhillbio.com
Employees: 210
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
RedHill Biopharma Ltd. primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections.
Recent news